Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meropenem - Pfizer/Sumitomo Pharma

Next Previous
X
Search
Drug Profile

Meropenem - Pfizer/Sumitomo Pharma

Alternative Names: ICI 194660; ICI 213689; Mepem; Meronem; Meropen; Meropenem hydrate; Merozen; Merrem; Optinem; SM-7338; Zeropenem®

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Chiesi Farmaceutici; PENTA Foundation; Pfizer; Sanofi; Sumitomo Pharma
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Febrile neutropenia; Skin and soft tissue infections
  • Discontinued Bacterial meningitis; Sepsis

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 24 Aug 2016 AstraZeneca plans to sell the commercialisation and development rights to late-stage small molecule antibiotics to Pfizer
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top